Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
RGEN's Cash to Debt is ranked higher than
98% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. RGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RGEN' s 10-Year Cash to Debt Range
Min: 63.71  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.87
RGEN's Equity to Asset is ranked higher than
76% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RGEN: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
RGEN' s 10-Year Equity to Asset Range
Min: 0.52  Med: 0.92 Max: 0.98
Current: 0.87
0.52
0.98
Interest Coverage 213.82
RGEN's Interest Coverage is ranked lower than
83% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RGEN: 213.82 )
Ranked among companies with meaningful Interest Coverage only.
RGEN' s 10-Year Interest Coverage Range
Min: 194.44  Med: 10000.00 Max: 9999.99
Current: 213.82
194.44
9999.99
F-Score: 4
Z-Score: 50.45
M-Score: -0.81
WACC vs ROIC
6.75%
12.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 13.85
RGEN's Operating margin (%) is ranked higher than
83% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. RGEN: 13.85 )
Ranked among companies with meaningful Operating margin (%) only.
RGEN' s 10-Year Operating margin (%) Range
Min: -312.44  Med: -30.84 Max: 186.01
Current: 13.85
-312.44
186.01
Net-margin (%) 10.03
RGEN's Net-margin (%) is ranked higher than
79% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. RGEN: 10.03 )
Ranked among companies with meaningful Net-margin (%) only.
RGEN' s 10-Year Net-margin (%) Range
Min: -224.93  Med: -19.38 Max: 192.3
Current: 10.03
-224.93
192.3
ROE (%) 6.06
RGEN's ROE (%) is ranked higher than
81% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. RGEN: 6.06 )
Ranked among companies with meaningful ROE (%) only.
RGEN' s 10-Year ROE (%) Range
Min: -47.55  Med: -8.16 Max: 82.79
Current: 6.06
-47.55
82.79
ROA (%) 5.38
RGEN's ROA (%) is ranked higher than
83% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. RGEN: 5.38 )
Ranked among companies with meaningful ROA (%) only.
RGEN' s 10-Year ROA (%) Range
Min: -43.4  Med: -6.18 Max: 75.79
Current: 5.38
-43.4
75.79
ROC (Joel Greenblatt) (%) 37.83
RGEN's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. RGEN: 37.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -779.69  Med: -66.34 Max: 1148.92
Current: 37.83
-779.69
1148.92
Revenue Growth (3Y)(%) 29.00
RGEN's Revenue Growth (3Y)(%) is ranked higher than
84% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. RGEN: 29.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -43.2  Med: 25.35 Max: 45.6
Current: 29
-43.2
45.6
EBITDA Growth (3Y)(%) 109.50
RGEN's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. RGEN: 109.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.7  Med: -1.00 Max: 109.5
Current: 109.5
-65.7
109.5
» RGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RGEN Guru Trades in Q2 2014

Jim Simons 707,200 sh (+51.76%)
Paul Tudor Jones Sold Out
Joel Greenblatt 14,914 sh (-3.81%)
» More
Q3 2014

RGEN Guru Trades in Q3 2014

Jim Simons 855,504 sh (+20.97%)
Joel Greenblatt 12,871 sh (-13.70%)
» More
Q4 2014

RGEN Guru Trades in Q4 2014

Joel Greenblatt 13,954 sh (+8.41%)
Jim Simons 694,304 sh (-18.84%)
» More
Q1 2015

RGEN Guru Trades in Q1 2015

Paul Tudor Jones 10,096 sh (New)
John Burbank 14,381 sh (New)
Jim Simons 860,165 sh (+23.89%)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 198.13
RGEN's P/E(ttm) is ranked lower than
87% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 41.10 vs. RGEN: 198.13 )
Ranked among companies with meaningful P/E(ttm) only.
RGEN' s 10-Year P/E(ttm) Range
Min: 3.19  Med: 28.81 Max: 762.86
Current: 198.13
3.19
762.86
Forward P/E 37.45
RGEN's Forward P/E is ranked lower than
74% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. RGEN: 37.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 200.60
RGEN's PE(NRI) is ranked lower than
88% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 37.80 vs. RGEN: 200.60 )
Ranked among companies with meaningful PE(NRI) only.
RGEN' s 10-Year PE(NRI) Range
Min: 3.19  Med: 28.62 Max: 534
Current: 200.6
3.19
534
P/B 12.07
RGEN's P/B is ranked lower than
84% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. RGEN: 12.07 )
Ranked among companies with meaningful P/B only.
RGEN' s 10-Year P/B Range
Min: 1.42  Med: 2.51 Max: 12.35
Current: 12.07
1.42
12.35
P/S 20.25
RGEN's P/S is ranked lower than
58% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. RGEN: 20.25 )
Ranked among companies with meaningful P/S only.
RGEN' s 10-Year P/S Range
Min: 2.74  Med: 6.23 Max: 20.65
Current: 20.25
2.74
20.65
PFCF 824.20
RGEN's PFCF is ranked lower than
95% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 33.86 vs. RGEN: 824.20 )
Ranked among companies with meaningful PFCF only.
RGEN' s 10-Year PFCF Range
Min: 3.18  Med: 27.04 Max: 842.4
Current: 824.2
3.18
842.4
POCF 171.70
RGEN's POCF is ranked lower than
87% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 31.61 vs. RGEN: 171.70 )
Ranked among companies with meaningful POCF only.
RGEN' s 10-Year POCF Range
Min: 3.15  Med: 30.25 Max: 99999999.99
Current: 171.7
3.15
99999999.99
EV-to-EBIT 133.14
RGEN's EV-to-EBIT is ranked lower than
86% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. RGEN: 133.14 )
Ranked among companies with meaningful EV-to-EBIT only.
RGEN' s 10-Year EV-to-EBIT Range
Min: -2288.9  Med: -7.00 Max: 2812.1
Current: 133.14
-2288.9
2812.1
Shiller P/E 215.97
RGEN's Shiller P/E is ranked lower than
88% of the 107 Companies
in the Global Biotechnology industry.

( Industry Median: 48.91 vs. RGEN: 215.97 )
Ranked among companies with meaningful Shiller P/E only.
RGEN' s 10-Year Shiller P/E Range
Min: 11.63  Med: 24.45 Max: 221.68
Current: 215.97
11.63
221.68
Current Ratio 6.33
RGEN's Current Ratio is ranked higher than
60% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. RGEN: 6.33 )
Ranked among companies with meaningful Current Ratio only.
RGEN' s 10-Year Current Ratio Range
Min: 1.55  Med: 8.74 Max: 44.57
Current: 6.33
1.55
44.57
Quick Ratio 5.41
RGEN's Quick Ratio is ranked higher than
58% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. RGEN: 5.41 )
Ranked among companies with meaningful Quick Ratio only.
RGEN' s 10-Year Quick Ratio Range
Min: 1.4  Med: 8.44 Max: 43.88
Current: 5.41
1.4
43.88
Days Inventory 152.64
RGEN's Days Inventory is ranked lower than
64% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. RGEN: 152.64 )
Ranked among companies with meaningful Days Inventory only.
RGEN' s 10-Year Days Inventory Range
Min: 70.97  Med: 146.26 Max: 730
Current: 152.64
70.97
730
Days Sales Outstanding 78.81
RGEN's Days Sales Outstanding is ranked lower than
61% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. RGEN: 78.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGEN' s 10-Year Days Sales Outstanding Range
Min: 6.73  Med: 29.79 Max: 126.28
Current: 78.81
6.73
126.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 35.83
RGEN's Price/Net Cash is ranked lower than
86% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. RGEN: 35.83 )
Ranked among companies with meaningful Price/Net Cash only.
RGEN' s 10-Year Price/Net Cash Range
Min: 1.93  Med: 5.72 Max: 26.4
Current: 35.83
1.93
26.4
Price/Net Current Asset Value 20.20
RGEN's Price/Net Current Asset Value is ranked lower than
79% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. RGEN: 20.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGEN' s 10-Year Price/Net Current Asset Value Range
Min: 1.69  Med: 4.34 Max: 18.02
Current: 20.2
1.69
18.02
Price/Tangible Book 16.16
RGEN's Price/Tangible Book is ranked lower than
84% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. RGEN: 16.16 )
Ranked among companies with meaningful Price/Tangible Book only.
RGEN' s 10-Year Price/Tangible Book Range
Min: 1.52  Med: 3.27 Max: 14.59
Current: 16.16
1.52
14.59
Price/Projected FCF 6.94
RGEN's Price/Projected FCF is ranked lower than
64% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. RGEN: 6.94 )
Ranked among companies with meaningful Price/Projected FCF only.
RGEN' s 10-Year Price/Projected FCF Range
Min: 0.69  Med: 1.06 Max: 5.11
Current: 6.94
0.69
5.11
Price/Median PS Value 3.24
RGEN's Price/Median PS Value is ranked lower than
85% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. RGEN: 3.24 )
Ranked among companies with meaningful Price/Median PS Value only.
RGEN' s 10-Year Price/Median PS Value Range
Min: 0.18  Med: 1.16 Max: 11.31
Current: 3.24
0.18
11.31
Price/Graham Number 11.94
RGEN's Price/Graham Number is ranked lower than
89% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. RGEN: 11.94 )
Ranked among companies with meaningful Price/Graham Number only.
RGEN' s 10-Year Price/Graham Number Range
Min: 0.54  Med: 2.03 Max: 8.8
Current: 11.94
0.54
8.8
Earnings Yield (Greenblatt) (%) 0.83
RGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. RGEN: 0.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 5.00 Max: 57.8
Current: 0.83
0.1
57.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RGN.Germany,
Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich's ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Reports First Quarter Fiscal Year 2010 Financial Results Aug 06 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
Market sends a message: Cash is king Jun 30 2015
IBD Market Wrap - 06/29/15 Jun 29 2015
Edited Transcript of RGEN presentation 3-Jun-15 12:00pm GMT Jun 26 2015
Repligen to Present at Jefferies 2015 Healthcare Conference May 26 2015
Repligen to Present at Jefferies 2015 Healthcare Conference May 26 2015
REPLIGEN CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
REPLIGEN CORP Financials May 16 2015
Very High-Profile Insider Selling Marks Roller-Coaster Market Week May 16 2015
Why Danaher's Purchase of Pall Means More M&A is on the Way May 13 2015
10-Q for Repligen Corp. May 10 2015
REPLIGEN CORP Files SEC form 10-Q, Quarterly Report May 08 2015
Repligen posts 1Q profit May 07 2015
Repligen posts 1Q profit May 07 2015
Repligen Reports First Quarter 2015 Financial Results May 07 2015
REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 07 2015
Repligen Reports First Quarter 2015 Financial Results May 07 2015
Q1 2015 Repligen Corp Earnings Release - Before Market Open May 07 2015
10-K for Repligen Corp. May 03 2015
Biotech execs remember MIT professor: ‘He inspired so many scientists’ May 01 2015
Repligen to Report First Quarter 2015 Financial Results Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK